secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch & Lomb Corp (BLCO)
CIK:        0001860742
Form:       8-K
Filed at:   2023-07-07T23:59:59+00:00
Accession:  0001193125-23-183284
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb to acquire Xiidra and other ophthalmology assets from Novartis for $1.75B cash plus milestones
--------------------------------------------------------------------------------

- Purchase price of $1.75B in cash at closing, plus up to $750M in milestone payments tied to sales and pipeline achievements.
- Transaction expected to close by end of fiscal year 2023, subject to HSR and other customary closing conditions.
- Bausch + Lomb subsidiary will make offers of employment to certain Novartis employees of the acquired business.
- Buyer has obtained debt financing commitments and Parent (Bausch + Lomb) has guaranteed Buyer's obligations.
- Termination fee of $100M payable by Buyer if certain breaches occur or if transaction fails to close under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523183284/0001193125-23-183284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523183284/d816837d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-183284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer